James Harte on Asundexian and Milvexian’s Strong, Dose-dependent Interferences in Coagulation Assays
James Harte, Assistant Lecturer/PhD Candidate on the School of Biochemistry and Cell Biology at University College Cork, proudly reposted from JTH Journal on LinkedIn:
”Delighted to see our work on the laboratory testing of asundexian, milvexian, from the EOLAS Research Group, shared by the Journal of Thrombosis and Haemostasis (JTH).”
JTH Journal shared on LinkedIn:
”Interferences associated with the factor XIa inhibitors asundexian and milvexian in routine and specialized coagulation assays and their removal by activated charcoal-based adsorbents.
This study shows that the emerging FXIa inhibitors asundexian and milvexian produce strong, dose-dependent interferences in coagulation assays — potentially leading to misinterpretation of hemostatic function.
Importantly, activated charcoal–based adsorbents (including DOAC-Stop) effectively removed these interferences, enabling accurate coagulation testing in treated plasma.”
Read the full paper here.
Article: Interferences associated with the factor XIa inhibitors asundexian and milvexian in routine and specialized coagulation assays and their removal by activated charcoal-based adsorbents
Authors: Gavin Buckley, Maeve Crowley, James Harte
Stay updated on all science in the field of coagulation disorders with Hemostasis Today.
-
Aug 20, 2025, 15:36Antoine Francis: LIFE - The Only Metric
-
Aug 20, 2025, 15:09World Stroke Academy: Rodrigo Guerrero Torrealba on Acute Vestibular Syndrome and Stroke
-
Aug 19, 2025, 14:27Living With a Blood Clot? Join NBCA’s Free PEP Talk for Support
-
Aug 19, 2025, 14:23EHC 2025: Young Voices Shaping the Future of Bleeding Disorders
-
Aug 19, 2025, 14:20Prakash Upreti: ECMO in High-Risk Pulmonary Embolism
-
Aug 20, 2025, 14:25Mattia Galli: Sex-related Differences in Platelet Reactivity in Patients Both On and Off Antiplatelet Therapy
-
Aug 20, 2025, 12:55Commentary from Giuseppe Lippi and Colleagues on Light Exposure, Platelet Function and Thrombus Formation
-
Aug 20, 2025, 05:48James Harte on Asundexian and Milvexian's Strong, Dose-dependent Interferences in Coagulation Assays
-
Aug 19, 2025, 18:18Hélène Gleitz-Broeders: Targeting Stromal Crosstalk to Reverse Bone Marrow Fibrosis
-
Aug 19, 2025, 17:58David Tregouet on Molecular Determinants of Thrombosis Recurrence Risk Across VTE Subtypes
-
Aug 18, 2025, 23:56Dr. Arun V. J Invites You to His Lecture on ‘AI and Data Sciences in Transfusion Medicine’ at the AI in Healthcare Conclave. Register now!
-
Aug 18, 2025, 23:50Safe and Efficient Thrombectomy with Artix System: Clinical Insights from Neil Desai and Colleagues
-
Aug 16, 2025, 14:42Mark Crowther Honors Davide Matino for Leading Promising Hemophilia Trial at McMaster University
-
Aug 14, 2025, 10:28Impressive 95% Clot Removal in a VTE Case: Symphony16F and Symphony24F Catheters
-
Jul 28, 2025, 14:55HORIBA Decoding High Efficiency in Hematology Lab: Free Online Workshop
-
Aug 20, 2025, 13:33Askat's Life with Hemophilia A after Access to Prophylactic Treatment Through the WFH Humanitarian Aid Program
-
Aug 19, 2025, 17:22Louise Bannon Encourages You to Support World Thrombosis Day!
-
Aug 17, 2025, 07:31Melissa Korn's story: Recognizing Pulmonary Embolism Symptoms Can Save Lives, NBCA
-
Aug 16, 2025, 14:18Christelle Orlando Highlights Breakthroughs in Thrombophilia Testing and AT Assays at ISTH 2025
-
Aug 15, 2025, 23:33Kacper Odziomek Excels in 2 Pharmacology Courses from Harvard Medical School